SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
NEW HAVEN, Conn., March 08, 2018 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a corporate overview at the Barclays Global Healthcare Conference on Thursday, March 15, 2018, at 11:15 a.m. ET at the Loews Miami Beach Hotel in Miami, FL.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its capabilities across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to bring life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman, PharmD, MPH Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
